Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15696989 | 0.82 | HSD11B1 (0.51) | HSD11B1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL20349499 | 0.77 | HSD11B1 (0.47) | HSD11B1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL19004888 | 0.77 | HSD11B1 (0.50) | HSD11B1KDM4EALDH1A1TDP1KMT2A | |
| SCHEMBL14595389 | 0.76 | HSD11B1 (0.54) | HSD11B1KDM4EALDH1A1TDP1KMT2A | |
| SCHEMBL16353728 | 0.74 | HSD11B1 (0.56) | HSD11B1KDM4EALDH1A1TDP1KMT2A | |
| SCHEMBL84852 | 0.73 | HSD11B1 (0.55) | HSD11B1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL5605768 | 0.71 | HSD11B1 (0.53) | HSD11B1KDM4EALDH1A1TDP1KMT2A | |
| SCHEMBL16938386 | 0.71 | HSD11B1 (0.61) | HSD11B1KDM4EALDH1A1TDP1KMT2A | |
| SCHEMBL8213345 | 0.71 | HSD11B1 (0.56) | HSD11B1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL2748651 | 0.71 | KDM4E (0.53) | HSD11B1KDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015766-A1 | Quinoline Derivatives as NK-3 and NK-2 Antagonists | GlaxoSmithKline S.P.A. & Laboratoire | 2007-01-18 | — | — | US | disclosed |
| US-20070015766-A1 | Quinoline Derivatives as NK-3 and NK-2 Antagonists | GlaxoSmithKline S.P.A. & Laboratoire | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015766-A1 | Quinoline Derivatives as NK-3 and NK-2 Antagonists | KCNK3, KCNQ3, ACKR3 | HSD11B1 2234/4885KDM4E 2581/4885ALDH1A1 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.